Волчаночный гломерулонефрит: клиника, морфология, прогно
Аннотация
Волчаночный гломерулонефрит (ВГН) является одним из серьезных и прогностически значимых проявлений системной красной волчанки (СКВ) [9, 18]. Механизм развития люпус-нефрита иммунокомплексный. В основе патогенеза лежит обусловленный генетически дефект апоптоза аутореактивных клонов Т- и В-клеток, приводящий к активации поликлональных В-лимфоцитов и формированию Т-зависимого иммунного ответа на аутоантигены - ДНК и нуклеосомы. Связывание антител к ДНК и других аутоантител с базальной мембраной почечных клубочков ведет к активации комплемента и рекрутированию клеток воспаления в клубочек [7, 18, 23, 28, 30, 33, 52, 63, 65, 67].
Ключевые слова
Список литературы
1. Захарова Е.В., Михайлова Н.А. Поражение почек при системной красной волчанке - клинико-морфологическая характеристика и результаты лечения. Нефрология 2003; приложение 1; 7: 182.
2. Михайлова Н.А., Захарова Е.В., Ипатьева Е.И. и др. Системная красная волчанка с поражением почек: клиническая характеристика и опыт лечения в нефрологическом отделении ГКБ им. С.П. Боткина за период с 1991 по 2001 гг. Нефрология и диализ 2002; 4: 186-191.
3. Насонов Е.Л., Баранов А.А., Шилкина Н.П. Васкулиты и васкулопатии. Верхняя Волга 1999; 515-574.
4. Насонов Е.Л. Антифосфолипидный синдром: диагностика, клиника, лечение. Русский медицинский журнал 2000; 6: 1184-1188.
5. Серов В.В., Варшавский В.А., Куприянова Л.А. Иммунопатология почек. М.: Медицина 1983: 176.
6. Соловьев С.К., Насонова В.А. Современные представления об интенсивной терапии системной красной волчанки. Русский медицинский журнал 2000; 6: 1195-1198.
7. Сперанский А.И., Насонова В.А., Рязанцева Т.А. и др. Сравнительное исследование активности иммуноглобулина G и лечебных препаратов нормального иммуноглобулина человека у больных с системной красной волчанкой, ревматоидным артритом у здоровых лиц. Ревматология 1991; 1: 22-24.
8. Тареева И.Е., Шилов Е.М., Краснова Т.Н. и др. Прогноз больных быстропрогрессирующим волчаночным нефритом при различных методах лечения. Тер. арх. 1994; 6: 4-7.
9. Тареева И.Е. Нефрология. М.: Медицина, 2000: 280-291.
10. Abraham M.A., Korula A., Jayakrishnan K. et al. Prognostic factors in diffuse proliferative lupus nephritis. J Assoc Physicians India 1999; 47: 862-865.
11. Appel G.B., Valeri A. The course and treatment of lupus nephritis. Ann Rev Med 1994; 45: 525-537.
12. Austin H.A. III et al. Prognostic factors in lupus nephritis. J of Med 1983; 75: 382-391.
13. Bansal V.K., Beto J.A. Treatment of lupus nephritis: A meta-analysis of clinical trials. Amer. J. Kidney Dis. 1997; 29: 193-199.
14. Bono L., Cameron J.S., Hicks J.A. The very long-term prognosis and complications of lupus nephritis and its treatment. Q J Med 1999; 92: 211-218.
15. Bootsma H. et al. Prevention of relapses in systemic lupus erythematosus. Lancet 1995; 345: 1595-1599.
16. Boumpas D.T., Austin H.A. III, Vaughn E.M. et al. Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. The Lancet 1992; 340: 741-745.
17. Cameron J.S. What is the role of long-term cytotoxic agents in treatment of lupus nephritis? J of Neph. 1993; 6: 172-176.
18. Cameron J.S. Lupus Nephritis. J Am Soc Nephrol 1999; 10: 413-424.
19. Churg J., Sobin L.H. Renal disease. Tokio: 1982: 127-131.
20. Cohen M.G., Li E.K., Lui S.F. et al. Intravenous cyclophosphamide in chinese patients with diffuse proliferative lupus nephritis. Austral. and N.Z. J Med 1992; 22: 740.
21. Colon P.J., Fisher C.A., Levesque M.C. et al. Clinical, biochemical and pathological predictors of poor response to intravenous cyclophosphamide in patients with proliferative lupus nephritis. Clin Nephrol 1996; 46: 170-175.
22. De Bandt M., Goycochea M.V., Meyer O. et al. Traitement du lupus erythemateux aigu dissimine par cyclophosphamide. Ann Med Interne 1999; 145: 175-187.
23. Decombes E., Droz D., Dronet L. et al. Renal vascular lesions in lupus nephritis. Medicine (Baltimore) 1997; 76: 355-368.
24. Derksen R.H., Hene R.J., Kater L. The long-term clinical outcome of 56 patients with biopsy-proven lupus nephritis, followed at a single center. Lupus 1992; 1: 97-103.
25. Donadio J.V. Treatment of membranous nephropathy in systemic lupus erythematosus. Nephrol Dial Trasplant 1992; (Suppl 1): 97-104.
26. Dooley M.A., Cosio F.G., Nachman P.H. et al. Mycophenolate mofetil therapy in lupus nephritis: Clinical observations. J Am Soc Nephrol 1999; 10: 833-839.
27. Doria A., Piccoli A., Vesco P. et al. Therapy of lupus nephritis: A two-year prospective study. Ann Med Intern 1994; 145: 307-311.
28. Esdaile J.M., Joseph L., McKenzie T. et al. The pathogenesis and prognosis of lupus nephritis: information from repeat renal biopsy. Semin Arthritis Rheum 1993; 23: 135-148.
29. Esdaile J.M. Current role of renal biopsy in patients with SLE. Baillieres Clin Rheumatol 1998; 12: 433-448.
30. Ferluga D., Jerse M., Virjak A. et al. Correlation among WHO classes, histomorphologic patterns of glomerulonephritis and glomerular immune deposits in SLE. Wien Klin Wochenschr 2000; 112: 629-701.
31. Ferrari P., Frey F.J. Immunosupressive therapy of glomerulonephritis - controlled studies. Ther Unsch 1993; 50: 119-129.
32. Font J., Ramos-Casals M., Cerevra R. et al. Cardiovascular risk factors and the long-term outcome of lupus nephritis. Q J Med 2001; 94: 19-26.
33. Furie R.A., Cash J.M., Cronin M.E. et al. Treatment of systemic lupus erythematosus with LJP 394. J of Rheumatol 2001; 28: 257-265.
34. Gladman D.D. Prognosis of systemic lupus erythematosus and factors that affect it. Curr Opin Rheumatol 1991; 5: 789-796.
35. Glicklich D., Acharaya A. Mycophenolate mofetil therapy for lupus nephritis refractory to intravenous cyclophosphamide. Am J Kidney Dis 1998; 31: 364-365.
36. Golan E., Weintal I., Bernheim J. et al. Long-term follow-up of the treatment of diffuse ptoliferative glomerulonephritis in patients with systemic lupus erythematosus. Harefuah 2002; 141: 324-328, 412.
37. Graninger W.B., Steinberg A.D., Meron G. et al. Interstitial nephritis in patients with systemic lupus erythematosus or manifestation of concominant Sjogren syndrome. Clin and Experim Rheumatol 1991; 9: 41-45.
38. Hayslett J.P., Esdaile J.M. Response to therapy as a predictor of outcome in lupus. Clin and Invest Med 1992; 15: 145.
39. Illei G.G., Austin H.A., Crane M. et al. Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. Ann Intern Med 2001; 135: 296-298.
40. Jacobsen S., Starklint H., Petersen J. et al. Prognostic value of renal biopsy and clinical variables in patients with lupus nephritis and normal serum creatinine. Scand Rheumatol 1999; 28: 288-299.
41. Kashagarian M. The role of kidney biopsy in the treatment of lupus nephritis. Ren Fail 1996; 18: 765-773.
42. Kater L., Derksen R.H., Hene R.J. Treatment of systemic lupus erythematosus: which options do we have for therapy regimens. Rheumatol Int 1991; 11: 137-140.
43. Korlet S.M., Lewis E.J., Schwartz M.M. et al. Factors predictive of outcome in severe lupus nephritis. Am J Kidney Dis 2000; 35: 901-914.
44. Lehman T.J.A. Current concepts in immunosupressive drug therapy of systemic lupus erythematosus. Journ of Rheumatol 1992; 19 (Suppl 33): 20-22.
45. Lee H.S., Najjais S.K., Kasinath B.S. et al. Course of renal pathology in patients with systemic lupus erythematosus. Am J of Medicine 1984; 77: 612-622.
46. Magil A.B. et al. Prognostic factors in diffuse proliferative lupus glomerulonephritis. Kidney Int 1988; 34: 511-517.
47. Martins L., Rocha G., Rodriges A. et al. Lupus nephritis: a retrospective review of 78 cases from a single center. Clin Nephrol 2002; 57: 114-119.
48. McGown J.R., Ellis S., Griffits M. et al. Retrospective analysis of outcome in a cohort of patients with lupus nephritis, treated between 1977 and 1999. Rheumatology 2002; 41: 981-987.
49. McInnes P.M., Schuttinga J., Sanslone W.K. et al. The economic impact of treatment of severe lupus nephritis with prednison and intravenous cyclophosphamide. Arthtitis Rheum 1994; 37: 1000-1006.
50. Mok C.C., Ho C.T., Sin Y.P. et al. Treatment of diffuse proliferative lupus nephritis: a comparison of two cyclophosphamide-containing regimens. Am J Kidney 2001; 38: 256-264.
51. Mok C.C., Ho C.T., Chan K.W. et al. Outcome and prognosis indicators of diffuse proliferative lupus glomerulonephritis, treated with sequential oral cyclophosphamide and azatioprine. Arthritis Rheum 2002; 46: 1003-1013.
52. Monova D., Argirova T., Monov S. Antiribosomal P antibodies in patients with lupus glomerulonephritis. Clinical Nephrology 2001; 55: 425-426.
53. Mosca M., Neri R., Gianessi S. et al. Therapy with pulse methylprednisolone and short-course pulse cyclophosphamide for diffuse proliferative glomerulonephritis. Lupus 2001; 10: 253-257.
54. Najafi C.C., Korbet S.M., Lewis E.J. et al. Significance of histologic patterns of glomerular injury upon long-term prognosis in severe lupus glomerulohephritis. Kidney Int. 2001; 59: 2156-2163.
55. Nossent H.C., Henzen-Logmans S.C., Vroom T.M. et al. Contribution of renal biopsy data in predicting outcome in lupus nephritis. Arthritis Rheum 1990; 33: 970-977.
56. Pasquali S., Banfi G., Zucchelli A. et al. Lupus membranous nephropathy: long-term outcome. Clinical Nephrology 1993; 39: 175-182.
57. Paton N.I.J., Cheong I.K.S., Kong N.C.T. et al. Risk factors for infections in Malaysian patients with SLE Q J Med 1996; 89: 531-538.
58. Pinto L.F., Senior J.M., Ceron J.A. et al. Nephropatia lupica. Acta Medica Colombiana 1992; 18: 157-163.
59. Ponticelli C. Current treatment recommendation for lupus nephritis. Drugs 1990; 40: 537-550.
60. Radhakrishnan J., Kunis C.L., D’Agati V. et al. Cyclosporine treatment of lupus membranous nephropathy. Clin Nephrol 1994; 42: 147-154.
61. Robert E., Parodi A., Rebora A. An Unusual Dermatologic Presentation of Systemic Lupus Erythematosus. Int J Dermatol 1992; 2: 31.
62. Shen K., Yn Y., Tang Z. et al. The prognosis biopsy-proven lupus-nephritis in chinese patients: long-term follow-up of 86 cases. Chin Med J 1997; 110: 502-507.
63. Shen W., Lu F., Zhang X. et al. A Study of Apoptosis in Renal Tissue of Diffuse Proliferative Lupus Nephritis. J Fudan Univ 2001; 28: 35-38.
64. Schwartz M.M., Bernstein J., Hill G.S. et al. Predictive value of renal pathologie in diffuse proliferative lupus glomerulonephritis. Kidney Int 1989; 36: 831-896.
65. Takahashi H., Moroi M. Antibody against platelet membrane glicoprotein VI in a patient with systemic lupus erythmatosus. Amer. J. of Hematol. 2001; 67: 262-267.
66. Tochimary H., Yasuda K., Takekekoshi Y. et al. Current topics in childhood lupus nephritis. Acta Paediatr Jpn 1993; 35: 480-487.
67. Tumlin J.A. Lupus nephritis: novel immunosupression modalities and future directions. Semin Nephrol 1999; 19: 67-76.
68. Valery A., Radhakrishnan J., Estes D. et al. Intravenous pulse cyclophosphamide treatment of severe lupus nephritis: a prospective five-year study. Clin Nephrol 1994; 42: 71-78.
69. Wallmam L., Stewart G., Chapman J. et al. Mycophenolate mofetil for treatment of refractoty lupus nephritis: four pilot cases. Aust NZ Med 2000; 30: 712-715.
70. Xie S.K., Feng S.F., Fu H. Long-term follow-up of patients with systemic lupus erythematosus. J Dermatol 1998; 25: 367-373.
71. Yeung C.K., Wong W.S., Ng M.T. et al. Crescentic lupus glomerulonephritis. Clin Nephrol 1984; 21: 251-258.
Рецензия
Для цитирования:
Захарова Е.В. Волчаночный гломерулонефрит: клиника, морфология, прогно. Нефрология и диализ. 2003;5(2):116-122.
For citation:
Zakharova E.V. Lupus glomerulonephritis: clinical features, morphology and prognosis. Nephrology and Dialysis. 2003;5(2):116-122. (In Russ.)
Просмотров:
11
Послать статью по эл. почте 